Introduction
Apoptosis can be initiated by dierent stimuli, including the withdrawal of survival factors, DNA damage, generation of reactive oxygen intermediates (ROIs) or by triggering speci®c cell surface receptors including CD95 and TNF receptor 1 (TNF-R1) (Vaux and Korsmeyer, 1999) . Ligation of the CD95 receptor leads to the induced binding of the adaptor protein FADD, which in turn recruits procaspase-8 to the receptor complex (Muzio et al., 1996) . Procaspase-8 is then activated by autoproteolysis, resulting in the release of active caspase-8 from the receptor complex . Caspase-8 belongs to a family of cysteine proteases with aspartate speci®city, which cleave their substrate proteins after a Asp residue (Cryns and Yuan, 1998) . The 11 dierent caspases known in humans so far play a central role for the execution of apoptosis and show dierent substrate speci®cities. These are de®ned by the amino acids immediately preceding the cleavage site, especially the P4 position four amino acids amino-terminal to the Asp residue. Accordingly, caspases are ordered into three groups: group I enzymes (caspase-1, -4 and -5) which are rather promiscuous compared with other caspases, group II enzymes (caspase-2, -3 and -7) and group III enzymes (caspase-6, -8, -9 and -10) (GarciaCalvo et al., 1998) . Caspases are synthesized as catalytically inactive proenzymes and their activation results in the proteolytic removal of the prodomain and the formation of an active tetramer, which is composed of two heterodimers formed by a small and a large subunit (NunÄ ez et al., 1998) . The apoptotic program is started by so-called initiator caspases such as caspase-8 and caspase-10, which become activated at the death receptors. Activation of these ®rst caspases initiates a proteolytic caspase cascade that transmits and ampli®es death signals by activating executioner caspases such as caspase-3 and -7 (Cryns and Yuan, 1998) . Caspases cleave a number of cellular key protiens resulting in alterations of cellular processes and in the disturbance of signaling pathways during apoptosis (Schulze-Ostho et al., 1998) . The concept of hierarchical caspase activation cascades is supported by the analyses of mice lacking the caspase-9 gene which are unable to activate caspase-3 . Caspase-9 de®cient T-cells of these mice are resistant to gradiation and the synthetic steroid dexamethasone, but remain sensitive to apoptosis induced by TNF-a or CD95. In contrast, caspase-8 negative cells resist CD95-and TNF-a-induced cell killing but readily die by exposure to dexamethasone or g-radiation (Varfolomeev et al., 1998) . These ®ndings support the idea of several independent cell death signaling pathways (Strasser et al., 1995; Scadi et al., 1998) . Caspase-3 activation is required for apoptosis in diverse settings including activation-induced cell death (AICD) of peripheral T-cells . AICD is induced by repeatedly triggering the T-cell receptor (TCR) without stimulation of accessory receptors such as CD28 (Varadhachary et al., 1997) . The absence of costimulation leads to a state of unresponsiveness termed anergy and the autocrine upregulation of the CD95 ligand (Schwartz, 1997) . In contrast, costimulation via CD28 severely lowers the threshold needed for full activation and results in the upregulation of IL-2 and other cytokines. IL-2 promotes the proliferation and dierentiation of T-cells and is therefore required for the full-blown immune response (Gomez et al., 1998) .
An early event in TCR signaling is the activation of cytoplasmic protein tyrosine kinases (PTKs), including members of the Syk (ZAP70 and Syk) and the Src (Lck and Fyn) family (Wange and Samelson, 1996) . Among the numerous PTK substrate proteins is the Vav1 proto-oncogene product (Gulbins et al., 1993) . This 95 kDa protein displays a wide variety of structural motifs including a N-terminal calponin homology (CH) domain, an acidic domain (AD), a Dbl-homology (DH) domain, a putative bipartite nuclear localization signal (NLS), a pleckstrin homology (PH) domain, a cysteine-rich domain (CR) and one SH2-domain anked by two SH3 domains (Romero and Fischer, 1996) . Its expression is restricted to cells of haematopoietic origin (Katzav et al., 1989) . Targeted gene disruption revealed the importance of Vav1 for receptor-mediated proliferation and TCR-mediated positive selection (Fischer et al., 1995; Tarakhovsky et al., 1995; Zhang et al., 1995; Turner et al., 1997) . Vav1 is furthermore important for the reorganization of the cytoskeleton and actin polymerization which contributes to the clustering of TCRs into patches and caps Holsinger et al., 1998) . Overexpression of Vav1 stimulates IL-2 expression by activating transcription factors such as NF-kB and by triggering the activity of mitogen-activated protein kinases (MAPKs) (Costello et al., 1999) . Phosphorylation and phosphatidylinositol-3,4,5-triphosphate (PIP3) binding of Vav1 activate its GDP/GTP exchange factor (GEF) activity for Rac (Crespo et al., 1997; Han et al., 1998) . The Vav1-derived and Rac-transmitted signals then activate the MAPK JNK (Song et al., 1999) and p38/HOG1 (Salojin et al., 1999) on parallel signaling routes.
In this study we provide several lines of evidence that Vav1 is a speci®c target for caspases during apoptosis in lymphoid cells. Vav1 is cleaved within its acidic domain at amino acid position 161 in vivo and in vitro, thus giving rise to the semi-stable intermediate Vav1p76. This amino-terminal truncated Vav1p76 form is able to activate JNK, but fails to trigger the activation of p38 and IL-2 transcription. The impact of the proteolytic inactivation of Vav1 during apoptosis on the cytoskeleton, the activation of signaling cascades and apoptosis is discussed.
Results

Caspase-dependent cleavage of Vav1 during apoptosis in lymphoid cells: inhibition by zVAD, zDEVD and CrmA
During experiments on the role of Vav1 in T-cell signaling we noticed signi®cantly reduced Vav1 levels in extracts from apoptotic cells. We followed this ®nding in more detail and added agonistic anti-APO-1 antibodies (Debatin et al., 1990) for various time periods to human Jurkat T-cell leukemia cells and investigated the fate of Vav1 in Western blot experiments ( Figure 1a) . The time-dependent disappearance of the full-length Vav1 protein coincided with the transient appearance of a new immunoreactive fragment of 76 kDa molecular weight (Vav1p76). No further Vav1 cleavage products were detectable irrespective of whether a monoclonal or a polyclonal antibody was used (data not shown). In parallel, the same extracts were tested for the processing of caspase-3, caspase-8 and poly (ADP ribose) polymerase (PARP), which is among the earliest cleaved substrates for the Ced-3 family of caspases (Lazebnik et al., 1994) . Both caspases and PARP were eciently cut.
Cleavage and thus activation of both caspases coincided with cleavage of Vav1, but PARP was cut with faster kinetics. Speci®c processing of the proteins was not observed in cells that were pretreated with the irreversible caspase inhibitors zDEVD-cmk or zVADfmk. The broad-range inhibitor zVAD-fmk inhibits all caspase activities and the peptide zDEVD-cmk displays some speci®city for caspase-3-like caspases (Villa et al., 1997; Garcia-Calvo et al., 1998) . In order to ensure that caspase-mediated Vav1 fragmentation is not restricted to a particular cell line, a similar experimental approach was performed for the human B-cell line SKW6.4 (Figure 1b) . The cleavage of both caspases and of the caspase substrate protein Vav1 appeared earlier than in Jurkat cells. The full-length form of Vav1 almost completely disappeared 240 min after the induction of apoptosis. Ecient CD95-induced cleavage of Vav1 was also seen in CEM C7 T-cells and the U937 macrophage cell line (data not shown). To ask whether the generation of the p76 cleavage product may be restricted to certain inducers of programmed cell death, Jurkat cells were exposed to a number of diverse and unrelated apoptotic stimuli ( Figure 1c ). The incubation times for the various apoptotic stimuli were chosen in order to allow detection of the intermediate Vav1p76 fragment rather than the complete disappearance of full-length Vav1. Cleavage of Vav1 and the generation of the Vav1p76 cleavage product was seen regardless of apoptosis induction by ligation of the death receptors TNF-R1 and CD95, the oxidant H 2 O 2 , or the protein kinase inhibitor staurosporine, showing that the Vav1 processing follows a common apoptotic pathway.
In order to get independent experimental evidence for the involvement of caspases in the cleavage of Vav1, we compared Vav1 cleavage between BJAB cells stably overexpressing either the wild-type form of the cowpoxvirus-encoded caspase inhibitor CrmA or an inactive CrmA point mutant (CrmA MUT ) ( Figure 2a ). Cells expressing wild-type CrmA showed no processing of the Vav1 protein after induction of CD95-mediated killing. In contrast, the inactive form of CrmA allowed caspase-dependent processing of Vav1 and the generation of Vav1p76. Accordingly, only cells expressing the wild-type form of CrmA were protected from CD95-induced apoptosis, whereas CrmA MUT expressing cells died after anti-APO-1 treatment in a time-dependent manner ( Figure 2b ).
In vitro cleavage of Vav1 in apoptotic Jurkat T-cell lysates
Lysates from apoptotic Jurkat T-cells have proven to be a useful system for studying the in vitro activity of caspases (Tan et al., 1997; Cosulich et al., 1997) . We therefore wanted to determine whether (1) caspases activated in apoptotic cells can directly cleave Vav1 and (2) determine the caspase cleavage sites in Vav1. (Figure 3 ). The Vav1 protein was stable in the control lysate, but a large portion was cleaved into the Vav1p76 fragment and the short 19 kDa fragment (Vav1p19) in apoptotic cell lysates. Vav1p19 could be detected only after longer exposure of the ®lm, which can be explained by the few methionines that are contained in this fragment. Lysates of the cells pretreated with the peptide inhibitors zVAD and zDEVD displayed no cleavage of Vav1, thus excluding Vav1 cleavage by non-caspase proteases. Furthermore, this experiment reveals the identity of Vav1p76 as a speci®c caspase cleavage fragment of Vav1. Also the in vitro translated control protein PARP was eciently cleaved by the apoptotic cell extracts, and its cleavage was not seen in the presence of peptide caspase inhibitors. A longer exposure of the in vitro cleavage experiment revealed the generation of several bands of minor intensity (marked with triangles) in addition to the main cleavage products Vav1p76 and Vav1p19 (marked with dots). These bands might originate from the cleavage of the background products contained in the in vitro translated input material of Vav1, which might be due to internal translational starts or premature termination of translation. However, we cannot exclude that a One-hundred mM of the caspase inhibitors zVAD-fmk and zDEVD-cmk were added 1 h prior to the addition of agonistic anti-APO-1 antibodies (1 mg/ml) for the given periods. Equal amounts of cellular proteins contained in total cell extracts were subjected to SDS ± PAGE and analysed by Western blotting for Vav1, caspase-3, caspase-8 and PARP. The full-length forms and the cleavage products are indicated. (b) SKW6.4 cells were treated and analysed for Vav1, caspase-3, caspase-8. The a-ERK1 immunoblot was included to ensure equal loading of protein. (c) Jurkat T-cells were treated either with TNF-a (2000 U/ml)/CHX (1 mg/ml) for 5 h, anti-APO-1 antibodies (1 mg/ml) for 90 min, H 2 O 2 (150 mM) for 6 h or with 2 mM staurosporine (stauro) for 3 h. Cleavage of the Vav1 protein was analysed by Western blotting, the molecular masses of protein markers are given. Representative experiments are displayed minor fraction of Vav1 is cleaved at further caspase cleavage sites.
Mapping of the Vav1 in vitro cleavage site by mutagenesis
In order to localize the caspase cleavage site which accounts for the generation of the Vav1p76 and Vav1p19 cleavage products, we scanned the Vav1 protein for the occurrence and distribution of caspase-3 consensus cleavage sites (DXXD), as schematically shown in Figure 4a . This analysis revealed a total of six putative caspase-3 consensus cleavage sites, which can give rise to a number of dierently sized fragments. This map suggests that Vav1p76 might consist either of a fragment starting from amino acid 151 or 162 to the C-terminus of the protein. This would leave amino acids 1 ± 150 or 1 ± 161 for the Vav1p19 fragment. To determine the exact Vav1 caspase cleavage site, the aspartic acids at positions 150 and 161 (and positions 100/104 and 442/445 as controls) were mutated to alanine. The generated point mutants and the wild-type (wt) version of Vav1 were in vitro translated in the presence of [
35 S]methionine and tested in dierent in vitro cleavage assays. The wild-type form of Vav1, the single point mutant D150A, and the double point mutants DD100/104AA and DD442/445AA were completely cut by apoptotic cell lysates into Vav1p76 (Figure 4b ). In contrast, only a fraction of the mutant Vav1 D161A protein was processed, but the generated cleavage product Vav1p77 migrated slightly slower than Vav1p76 (Figure 4b , compare lanes 8 and 10). S-methionine-labeled Vav1 by extracts from apoptotic Jurkat T-cells. Left: Jurkat T-cells were treated as speci®ed in the ®gure. Preincubation with 50 mM of zVAD-fmk or zDEVD-cmk was done 1 h prior to the addition of anti-APO-1 antibodies (1 mg/ml) for 2.5 h. Postnuclear cell extracts were prepared and 100 mg extract was incubated for 6 h with 2 ml of in vitro translated S-labeled wild-type Vav1 protein, and mutants Vav1 DD100/104AA, D150A, D161A and DD150/161AA, respectively (Figure 4c ). The wild-type Vav1 protein and the D104A and D150A mutants were completely cleaved by recombinant caspase-3, thus generating the Vav1p76 fragment. The Vav1 D161A mutant was much less eciently cleaved and gave rise to the Vav1p77 cleavage product with slightly retarded mobility, when compared to Vav1p76. This size dierence may be explained by the use of an alternative cleavage site at position 150, which is only used when the site at 161 is not functional (Figure 4b, lane 8) . This assumption was directly tested by analysing cleavage of the Vav1 double point mutant DD150/ 161AA. The Vav1 DD150/161AA double mutant was protected from caspase-3 cleavage and neither the Vav1p76 nor the Vav1p77 cleavage product was generated, showing that the generation of Vav1p77 is due to the use of the alternative cleavage site at position 150. The partial reduction of the full-length form of Vav1 DD150/161AA in the presence of caspase-3 is not due to speci®c cleavage and was not seen after shorter incubation times with caspase-3, which still allowed the complete cleavage of the other Vav1 variants (data not shown). Only the cleavage product Vav1p76, but not Vav1p77, comigrated exactly with the cleavage product of Vav1 that was generated during apoptosis in intact T-cells, thereby identifying Vav1p76 as the biologically relevant processing intermediate (data not shown). with empty vector, vector encoding the wild-type Vav1 protein or the double mutant Vav1 DD150/161AA. Apoptosis was induced by treatment with 2 mM staurosporine and the fate of Vav1 was analysed by Western blotting (Figure 5a ). Whereas the wild-type Vav1 protein was processed and disappeared 6 h after induction of apoptosis, the Vav1 double mutant was not degraded even 9 h after the onset of apoptosis. In contrast, the single mutant Vav1 D161A point was cut with the similar kinetics as wild-type Vav1 (data not shown), revealing that the adjacent alternative cleavage sequence DQID 150 D is also used in vivo. Of note, this alternative site is only used in vivo upon inactivation of the relevant site DLYD 161 C. In parallel, the cells were tested for a possible role of Vav1 or its cleavage products in apoptosis. The staurosporine-induced apoptosis of HeLa cells transfected with the empty expression vector was indistinguishable from apoptosis of HeLa cells transfected with the wild-type form of the non-degradable version of Vav1 (Figure 5b ). However, we could not determine a possible role of Vav1 and its cleavage products for apoptosis in T-cells, since the cytotoxicity of Vav1 and Vav1 DD150/ 161AA prevented the generation of stably transfected Jurkat cell lines. Therefore, the Vav1 protein or its cleavage products are neither pro-nor antiapoptotic in these two experimental settings.
The Vav1p76 fragment activates JNK, but fails to induce p38 phosphorylation
We have previously identi®ed Vav1 as an activator of the MAPkinases p38 and JNK and of transcription factors binding to the CD28RE/AP composite element in the IL-2 promoter. Therefore we tested whether the Vav1 cleavage product Vav1p76 is competent in mediating these activation processes. Jurkat T-cells were cotransfected with a vector encoding Flag-tagged p38 together with the wild-type form of Vav1 or an expression vector encoding Vav1p76 (amino acids 162 ± 846, N-terminally fused to a Flag tag). We also included a signaling incompetent, dominant negative form of Vav1 lacking an important part of the DH domain, thus resulting in an impaired GEF function (Vav1DGEF). The tagged p38 protein was immunoprecipitated and analysed for its Thr180/Tyr182 phosphorylation by Western blotting (Figure 6a ). Dose-dependent stimulation of p38 phosphorylation was seen upon cotransfection of the wild-type form of Vav1, but not of Vav1DGEF. The gradual overexpression of Vav1p76 failed to induce p38 phosphorylation, when compared to wild-type Vav1. Similar results were obtained when the impact of gradual overexpression of these Vav1 forms on endogenous p38 activity was determined (data not shown). In an experimental approach analogous to the one used to study p38 activation, we gradually overexpressed the three dierent Vav1 constructs together with a HAtagged JNK expression vector. The tagged JNK protein was immunoprecipitated and its kinase activity was determined by immunecomplex kinase assays (Figure 6b ). Increasing amounts of transfected Vav1 resulted in a strong induction of JNK kinase activity. This activity was only seen when Vav1 was expressed for more than 40 h. In contrast, Vav1DGEF has almost completely lost its JNK activating ability, but Vav1p76 was still capable of triggering the activation of this MAPkinase in a dose-dependent fashion almost as ecient as the wild-type Vav1 protein. These experiments show that the N-terminal 161 amino acids of Vav1 are of minor importance for submitting the JNK activating signal, but are essential for the activation of p38.
Vav1 p76 in impaired in activating transcription factors and completely fails to trigger IL-2 transcription
The promoter of the IL-2 gene harbors binding sites for numerous transcription factors including NF-AT, NF-kB, Octamer factors and the CD28RE/AP composite element (Jain et al., 1995) . Consequently we tested the ability of the Vav1 cleavage product Vav1p76 to activate these dierent transcription factors contributing to IL-2 transcription in T-cells. Jurkat cells were transfected with expression vectors for Vav1, Vav1D GEF or Vav1p76 together with distinct luciferase reporter genes controlled by multimerized binding sites for the respective transcription factors (Figure 7a ). Wild-type Vav1 eciently induced gene expression from NF-AT-, AP-1-, NF-kB-and CD28RE/APdependent luciferase genes. In contrast, Vav1DGEF failed to induce the activity of these transcription factors. Vav1p76 displayed a strongly impaired ability to activate NF-kB-and AP-1-dependent luciferase production, but retained a faint residual activating capacity for the activation of these transcription factors when compared to the completely inactive dominant negative mutant Vav1DGEF. Vav1p76 completely failed to activate CD28RE/AP-dependent transcription, but still activated NF-AT to a certain extent. Since all of the transcription factors tested here contribute to transcription from the IL-2 promoter, we compared the ability of wild-type Vav1, Vav1DGEF and Vav1p76 to direct transcription from this promoter. Jurkat T-cells were transiently transfected with a luciferase reporter construct fused to the human IL-2 promoter together with increasing concentrations of the respective Vav1 expression plasmids (Figure 7b ). IL-2 transcription was dose-dependently boosted by Vav1 wild-type. In contrast, the p76 form of Vav1 not only failed to increase IL-2 transcription, but even acted in a transdominant negative fashion such as Vav1DGEF.
Discussion
Here we have shown that Vav1 is cleaved by caspases during apoptosis in lymphoid cells, resulting in the loss of IL-2 transcription. The inhibitory eect of peptide caspase inhibitors like zDEVD-cmk does not allow an identi®cation of the individual caspase(s) that cleave the substrate protein Vav1, since the peptide inhibitors lack absolute speci®city for individual caspases. Direct evidence for the involvement of caspase-3 in the cleavage of Vav1 was obtained from experiments revealing that in vitro translated, The caspase-dependent cleavage of PARP occurs with a signi®cantly faster kinetics than the cleavage of Vav1, which might rely on dierent accessibilities of the cleavage sites or re¯ect the participation of dierent subsets of caspases for these two substrates. This study locates the cleavage site used for the destruction of Vav1 at amino acid 161. This cleavage site seems to be of high importance, since it is evolutionary conserved between several mammals ± human, mouse and rat ± and is also found at exactly the same position within the Vav2 and Vav3 proteins (data not shown). The ubiquitously expressed Vav2 and Vav3 proteins function also as activators of GTPases (Schuebel et al., 1998; Movilla and Bustelo, 1999) . The question whether Vav2 and Vav3 are also cleaved at this conserved caspase cleavage site during apoptosis remains to be tested in future experiments.
The change of aspartic acid 161 within Vav1 to alanine resulted in the use of the adjacent alternative caspase-3 consensus cleavage site DQID 150 D. Mutation of aspartate at the physiologically relevant cleavage site 161 and at 150 within the alternative site protected the Vav1 protein from cleavage, implying that the cut at position 161 is the prerequisite for the subsequent processing of Vav1 either by further caspases or by other proteolytic enzymes. This alternative site might be without any signi®cance for the cleavage of the wild-type protein, since it is exclusively cut at the physiologically relevant site at position 161. Alternatively, one might speculate whether this alternative site represents a`fail-safe' mechanism by which the destruction of Vav1 at a similar position is ensured. Both cleavage sites are located within the acidic domain and chop o the N-terminal part containing a CH domain (Katzav, 1995) . In this context it is noteworthy that the oncogenic form of Vav1 arises from the deletion of 67 N-terminal amino acids from Vav1 and induces tumors in nude mice (Katzav et al., 1989; Coppola et al., 1991) . Although this N-terminal truncation of Vav1 induces its oncogenic activity, the ability to induce NF-AT-dependent transcription is reduced (Wu et al., 1995) . Similar to Vav1p76, the oncogenic form of Vav1 is still functioning in the activation of JNK (Germani et al., 1999) , indicating Figure 6 The Vav1 cleavage product Vav1p76 activates JNK but fails to induce p38 phosphorylation. (a) Increasing amounts of the indicated Vav1 expression vectors were cotransfected into Jurkat T-cells together with Flag-tagged p38 (5 mg). One day later, p38 was immunoprecipitated with a monoclonal anti-Flag antibody. Immunoprecipitates were resolved by SDS ± PAGE and subsequently analysed for p38 expression and phosphorylation. Samples of whole cell lysates were immunoblotted for the expression levels of the various transfected Vav1 proteins (lower). (b) Jurkat T-cells were transiently transfected with increasing amounts of the indicated Vav1 expression vectors together with 5 mg of HA-tagged JNK. Two days later, JNK was immunoprecipitated from cell lysates and its activity was determined by immune complex kinase assays using recombinant GST-c-Jun (5-89) as substrate (upper) . A sample of each lysate was analysed by immunoblotting for protein expression of JNK, Vav1 wild-type, Vav1DGEF and Vav1p76 (lower). Representative Western blots, autoradiograms from reducing SDS gels and quantitative evaluations obtained by phosphoimaging are shown that the N-terminal portion is not important for this activation process. We could not test a possible function of this N-terminal Vav1p19 protein, since it was not stably expressable in all cell lines tested. Furthermore, the p19 fragment was not detectable in extracts from apoptotic Jurkat cells previously transfected with N-terminally Flag-tagged Vav1 (data not shown). Since this fragment is extremely unstable, it is reasonable to assume that it will not signi®cantly in¯uence gene expression. This very N-terminal stretch of 161 amino acids seems to comprise an important function for the transmission of signals which activate certain transcription factors and the MAPkinase p38. Our results of an important role for Vav1 in the activation of JNK do not contradict the data obtained from thymocytes derived from Vav1 knockout mice, which were shown to retain their inducible JNK activation Holsinger et al., 1998) . Of note, these ®ndings were obtained by a loss-of-function approach and are therefore not inconsistent with our results of a Vav1-mediated JNK activation, which were measured by a gain-of-function approach. It is conceivable that the thymocytes to peptide-speci®c and a-CD3/a-CD28-mediated apoptosis . However, these Vav1 7/7 lymphocytes are not changed in their susceptibility to programmed cell death induced by other apoptotic stimuli such as CD95 ligation, PMA/ ionophore exposure or dexamethasone treatment , suggesting that the direct eect of Vav1 on apoptosis is restricted to certain apoptotic inducers only in a specialized subset of T-cells. The cleavage of Vav1 also impairs its potent NF-kB activating function. This transcription factor plays a dual role in apoptosis as a signal-dependent antagonist or promoter of cell death (Baichwal and Baeuerle, 1997) . NF-kB activation protects from some apoptotic stimuli such as TNF-a, but is required for other cell death inducers such as H 2 O 2 and a-CD3 triggering (Dumont et al., 1999; Hettmann et al., 1999) . Therefore, the inactivation of Vav1 may either antagonize apoptotic processes requiring NF-kB activation or promote apoptosis in a situation were NF-kB has a protective function. It remains to be investigated whether the cleavage and thus inactivation of Vav1 described here may lead to a local decrease of IL-2 and thereby spread of the apoptotic signal to neighboring, IL-2 dependent T-cells. This scenario might play a role during the termination phase of a ®nished immune response.
Gene disruption experiments and functional studies reveal Vav1 as an important upstream activator of numerous signaling pathways, thereby exerting pleiotropic eects on cell proliferation, MAPkinase activation, trancription factor recruitment and cytoskeletal organization (Cantrell, 1998) . Since Vav1 is located at an early point for many Ca 2+ -dependent and -independent signaling cascades, its targeted inactivation during apoptosis prevents the activation of the MAPK p38 as well as the induction of various transcription factors. Since the targeted deletion of Vav1 in mice leads to similar eects than the actin polymerization inhibitor cytochalasin D Holsinger et al., 1998) , the elimination of Vav1 probably also disables the cytoskeleton, which is a frequent caspase target. Taken together, the inactivation of Vav1 by caspases leads to pleiotropic eects: loss of signal transmission for several signaling cascades and transcription factors and the prevention of IL-2 transcription. Since the proteolytic caspasedependent destruction of Vav1 aects so many processes, it is presumably much more economical for the death machinery than cleaving the variety of its downstream targets.
Materials and methods
Antisera and reagents
The a-Flag antibody (M2) was purchased from Sigma, the a-HA antibody (12CA5) from Roche Molecular Biochemicals, a-Myc (9E10) and a-Vav1 monoclonal and polyclonal antibodies were from Upstate Biotechnology; a-phosphop38 from New England Biolabs, a-caspase-3 and a-Erk1 (MK12) was purchased from Transduction Laboratories. We thank Dr A BuÈ rkle (DKFZ, Heidelberg, Germany) for a-PARP antibodies and Dr ME Peter (DKFZ, Heidelberg, Germany) for the a-caspase-8 (C15) antibodies . The caspase inhibitors N-benzyloxycarbonyl-Val-Ala-DL-Asp-fmk (zVAD-fmk) and N-benzyloxycarbonyl-AspGlu-Val-Asp-cmk (zDEVD-cmk) were from Bachem. Recombinant, active caspase-3 and -8 were from Pharmingen. All other reagents were from Sigma or Roche Molecular Biochemicals.
Cell culture, transfection and stimulation
HeLa cells were grown in Dulbecco's modi®ed Eagle medium supplemented with 10% (v/v) fetal calf serum and 1% (v/v) penicillin/streptomycin. They were transfected using the Superfect 1 reagent (Qiagen Inc.) according to the instructions of the manufacturer. Jurkat T leukemia cells expressing the large T antigen were grown at 378C and 5% CO 2 in RPMI 1640 medium containing 10% (v/v) heat-inactivated fetal calf serum, 10 mM HEPES, 1% (v/v) penicillin/streptomycin (all from Life Technologies) and 2 mg/ml G418. 3610 7 Jurkat Tcells were transfected in 400 ml serum-free RPMI medium by electroporation using a BioRad gene pulser and 0.4 cm cuvettes at 250 V/950 mF with constant amounts of DNA. SKW6.4 cells and BJAB cells stabile expressing CrmA and CrmA MUT (Tewari et al., 1995) were grown at 378C in RPMI 1640 medium containing 10% (v/v) heat-inactivated fetal calf serum, 10 mM HEPES, 1% (v/v) penicillin/streptomcyin. Apoptosis was induced by adding anti-APO-1 antibodies (1 mg/ml) together with protein A (10 ng/ml) for crosslinking.
Cloning and site-directed mutagenesis
The Vav1 cDNA was subcloned in pBluescript II SK(7) (Stratagene) for mutagenesis. Site-directed mutagenesis was done using the Quickchange Kit (Stratagene) according to the instructions of the manufacturer. All point mutants were sequenced and Vav1 D161A and Vav1 DD150/161AA were subcloned into a pEF-BOS-derived vector. Flag-Vav1p76 was generated by PCR, inserted in pBluescript II SK(7), sequenced and subcloned into a pEF-BOS-derived vector. The PARP cDNA (kindly provided by Dr A BuÈ rkle, DKFZ, Heidelberg, Germany) was subcloned for in vitro transcription/translation into pBluescript II SK(7). Details about the primers and the generation of the plasmid constructs described here can be obtained from the authors upon request.
Immunoprecipitation experiments and Western blotting
3610
7 Jurkat T-cells were washed with phosphate-buered saline (PBS) and the pellets were resuspended on ice for 30 min in 250 ml of NP-40 lysis buer (50 mM Tris/HCl pH 7.5, 150 mM NaCl, 1 mM phenylmethylsulfonyl¯uoride, 10 mM NaF, 0.5 mM sodium vanadate, leupeptine (10 mg/ml), 1% (v/v) NP-40 and 10% (v/v) glycerol). The cell debris was pelleted upon centrifugation with 14 000 r.p.m. at 48C for 10 min. Equal amounts of protein contained in the supernatant were either directly analysed by Western blotting or immunoprecipitated by adding 1 to 2 mg of antibody and 25 ml of protein A/G plus agarose (Santa Cruz Inc.). After rotation for at least 4 h on a spinning wheel at 48C, the immunoprecipitates were washed ®ve times in lysis buer. Immunoprecipitates were boiled in 16SDS sample buer and separated by SDS ± PAGE prior to immunoblotting. Subsequently, the proteins were transferred from the SDS gel onto a polyvinylidene di¯uoride (PVDF) membrane (Millipore) using a semi-dry blotting apparatus (Bio-Rad). The membrane was blocked with 5% non-fat dry milk powder in TBST buer (25 mM Tris/HCl pH 7.4, 137 mM NaCl, 5 mM KCl, 0.7 mM CaCl 2 , 0.1 mM MgCl 2 , 0.1% (v/v) Tween-20). The membrane was then incubated in a small volume of TBST containing various dilutions of the antibodies. After further incubation with appropriate secondary antibodies coupled to horseradish peroxidase, the immunoreactive bands were visualized by enhanced chemiluminescence according to the instructions of the manufacturer (Amersham Lifescience).
Detection of apoptosis by FACS analysis
Apoptosis was measured by determining the percentage of hypoploid cells after lysis of the cells in a hypotomic buer containing 50 mg/ml propidium iodide, 0.1% (w/v) sodium citrate and 0.1% (v/v) Triton X-100 (all from Sigma). DNĀ uorescence was determined in a FACScan as described (Nicoletti et al., 1991) , and the results were analysed with CELLQuest software (Becton Dickinson).
JNK assays
Cells were lysed in NP-40 lysis buer and the JNK protein contained in the cell lysate was precipitated by the addition of 1 mg of a-HA antibody (12CA5) and 25 ml of protein A/G plus agarose. The precipitate was washed four times in lysis buer and two times in kinase buer (20 mM HEPES/KOH pH 7.4, 25 mM b-glycerophosphate, 2 mM DTT, 20 mM MgCl 2 ). The kinase assay was performed in a ®nal volume of 20 ml kinase buer containing 2 mg of bacterially expressed GST-c-Jun protein, 20 mM ATP and 5 mCi g-32 P-ATP. After incubation for 20 min at 308C, the reaction was stopped by the addition of 56SDS loading buer. After separation by SDS ± PAGE, the gel was ®xed, dried and quanti®ed using a phosphoimager.
Expression vectors and reporter constructs
The NF-kB-dependent luciferase construct (Hehner et al., 1998) and the Flag-tagged wild-type form of Vav1 and the Myc-tagged Vav1DGEF version were previously described (Hehner et al., submitted) . The IL-2-promoter luciferase construct was obtained from Dr W Kolanus (Munich, Germany) and the NF-AT-dependent reporter was from Dr E Ser¯ing (WuÈ rzburg, Germany). 46CD28RE/AP-Luc constructs were generous gifts from DA Weiss (Shapiro et al., 1997) and the 36AP-1 Luc plasmid was a gift from Dr P Angel (DKFZ, Heidelberg, Germany).
In vitro caspase cleavage assays
The Vav1 proteins were labeled with 35 S-methionine (Amersham Lifescience) using the coupled TnT in vitro transcription/translation system from rabbit reticulocyte lysates according to the instructions of the manufacturer (Promega Inc.). Jurkat T-cells were treated for 2.5 h with 1 mg/ml anti-APO-1 and lysed in cleavage buer (25 mM HEPES pH 7.4, 5 mM EDTA, 5 mM EGTA, 2 mM DTT, 10 mM Digitonin, 0.5 mM PMSF, 10 mg/ml Aprotinin, 10 mg/ml Leupeptin). One-hundred mg of postnuclear apoptotic Jurkat T-cell lysate or 100 ng of recombinant caspase-3 were incubated with 35 Slabeled proteins in caspase cleavage buer at 378C for 6 h. After separation by SDS ± PAGE, the gel was ®xed (10% (v/ v) acetic acid, 20% (v/v) methanol). The radioactive signals were enhanced using Amplify 1 (Amersham) prior to drying and autoradiography.
Luciferase assays
Cells were harvested by centrifugation and washed twice with cold PBS buer and lysed in reporter lysis buer (25 mM Tris-Phosphate, 2 mM DTT, 2 mM CDTA, 10% (v/v) glycerol, 1% (v/v) Triton X-100). The luminometer (Duo Lumat LB 9507, Berthold) was programmed to inject 50 ml of assay buer (40 mM Tricine, 2.14 mM (MgCO 3 ) 4 Mg (OH) 2 65 H 2 O, 5.34 mM MgSO 4 , 0.2 mM EDTA, 66.6 mM DTT, 540 mM CoA, 940 mM luciferin, 1.06 mM ATP) and to measure light emission for 10 s after injection.
